Host Interface of Cystic Fibrosis and p. aeruginosa

Year : 2024 | Volume : | : | Page : –
By

Debanjali Adhikary,

  1. Student, Amity Institute of Biotechnology, Amity University Noida, Uttar Pradesh, India

Abstract

A clash between microbial infection and host immunity can contribute to multiple diseases. Cystic fibrosis is one of those diseases. It’s an autoimmune disorder and hyperinflammatory disease, caused by pseudomonas aeruginosa, it’s the most predominant pathogen causing this disease. The progression of the lung infection cystic fibrosis is driven by host pathogen interface that focuses on the host and the bacterial factors. The disease has an interplay between the host, pathogen and the microbiota together. Cystic fibrosis is the most predominant genetic and life risk diseases among the population. It’s a lung disease. Around 40,000 people are living with this disease in the United States of America and over 80,000 people worldwide. Its more prone to the parts of northern America. In the 1940’s this disease was called paediatric disease as it developed in infancy and the kids used to die and not lived over infancy. But in the present scenario with further advancement, in the diagnostic strategies life span of a cystic fibrosis patient has increased to 34 years in the United States and 40 in London. Cystic fibrosis is a pulmonary disease that include reactive oxygen species [ROS] and antimicrobial peptides. The pathogen has an innate response to the virulence factors and bacterial factors. So, we must review the current understanding of the host pathogen interaction between pseudomonas aeruginosa and cystic fibrosis by studying the progression of the disease, study of the virulence and the adaptive factors, reactive oxygenic species, and the colocalization of the host.

Keywords: ROS, cystic fibrosis, lung infection, inflammation, immunity, pseudomonas aeruginosa

How to cite this article:
Debanjali Adhikary. Host Interface of Cystic Fibrosis and p. aeruginosa. Research & Reviews: A Journal of Microbiology & Virology. 2024; ():-.
How to cite this URL:
Debanjali Adhikary. Host Interface of Cystic Fibrosis and p. aeruginosa. Research & Reviews: A Journal of Microbiology & Virology. 2024; ():-. Available from: https://journals.stmjournals.com/rrjomv/article=2024/view=177419

References

  1. O’Sullivan, B. P., & Freedman, S. D. (2009). Cystic fibrosis. Lancet (London, England), 373(9678), 1891–1904. https://doi.org/10.1016/S0140-6736(09)60327-5
  2. Aghamohammadi A, Keivanfar M, Navaei S, Shirzadi R, Masiha F, Allameh Z, Heydari A, Eslami S, Azizi G, Reisi M, Modaresi M. First cystic fibrosis patient registry annual data report-cystic fibrosis foundation of Iran. Acta Medica Iranica. 2019 Feb 13:33-41.
  3. Scotet V, Duguépéroux I, Saliou P, Rault G, Roussey M, Audrézet MP, Férec C. Evidence for decline in the incidence of cystic fibrosis: a 35-year observational study in Brittany, France. Orphanet journal of rare diseases. 2012 Dec;7:1-7.
  4. Spoonhower KA, Davis PB. 2016. Epidemiology of cystic fibrosis. Clin Chest Med 37:1– 8. https://doi.org/10.1016/j.ccm.2015.10.002.
  5. Elborn JS. Digital healthcare in cystic fibrosis. Learning from the pandemic to innovate future care (Commentary). Journal of Cystic Fibrosis. 2021 Dec 1;20:64-6.
  6. Taylor-Robinson D, Archangelidi O, Carr SB, Cosgriff R, Gunn E, Keogh RH, MacDougall A, Newsome S, Schlüter DK, Stanojevic S, Bilton D. Data resource profile: the UK cystic fibrosis registry. International journal of epidemiology. 2018 Feb 1;47(1):9-10e
  7. Vallières E, Elborn JS. Cystic fibrosis gene mutations: evaluation and assessment of disease severity. Advances in Genomics and Genetics. 2014 Oct 21:161-72.
  8. Mall MA, Mayer-Hamblett N, Rowe SM. Cystic fibrosis: emergence of highly effective targeted therapeutics and potential clinical implications. American journal of respiratory and critical care medicine. 2020 May 15;201(10):1193-208.
  9. Bradbury NA. CFTR and cystic fibrosis: a need for personalized medicine. Studies of Epithelial Transporters and Ion Channels: Ion Channels and Transporters of Epithelia in Health and Disease-Vol. 3. 2020:547-604.
  10. Cutting GR. 2015. Cystic fibrosis genetics: from molecular understanding to clinical application. Nat Rev Genet 16:45–56. https://doi.org/10 .1038/nrg3849.
  11. De Boeck K, Vermeulen F, Dupont L. 2017. The diagnosis of cystic fibrosis. Presse Med 46:e97– e108. https://doi.org/10.1016/j.lpm.2017 .04.010.
  12. Smyth AR, Bell SC, Bojcin S, Bryon M, Duff A, Flume P, Kashirskaya N, Munck A, Ratjen F, Schwarzenberg SJ, Sermet-Gaudelus I, Southern KW, Taccetti G, Ullrich G, Wolfe S. 2014. European cystic fibrosis society standards of care: best practice guidelines. J Cyst Fibros 13:S23–S42. https://doi.org/10.1016/j.jcf.2014.03.010.
  13. Farrell PM, White TB, Ren CL, Hempstead SE, Accurso F, Derichs N, Howenstine M, McColley SA, Rock M, Rosenfeld M, Sermet-Gaudelus I. Diagnosis of cystic fibrosis: consensus guidelines from the cystic fibrosis foundation. The Journal of pediatrics. 2017 Feb 1;181:S4-15.
  14. Chin M, Aaron SD, Bell SC. The treatment of the pulmonary and extrapulmonary manifestations of cystic fibrosis. La Presse Médicale. 2017 Jun 1;46(6):e139-64..
  15. Strausbaugh SD, Davis PB. Cystic fibrosis: a review of epidemiology and pathobiology. Clinics in chest medicine. 2007 Jun 1;28(2):279-88.
  16. Starner TD, McCray PB, Jr, American College of Physicians, American Physiological Society. 2005. Pathogenesis of early lung disease in cystic fibrosis: a window of opportunity to eradicate bacteria. Ann Intern Med 143:816 –822. https://doi.org/10.7326/0003-4819-143-11-200512060 -00010.
  17. Rosenow T, Oudraad MCJ, Murray CP, Turkovic L, Kuo W, de Bruijne M, Ranganathan SC, Tiddens HAWM, Stick SM, Australian Respiratory Early Surveillance Team for Cystic Fibrosis. 2015. PRAGMA-CF. A quantitative structural lung disease computed tomography outcome in young children with cystic fibrosis. Am J Respir Crit Care Med 191:1158 –1165. https://doi.org/10.1164/rccm.201501-0061OC.
  18. Sly PD, Gangell CL, Chen L, Ware RS, Ranganathan S, Mott LS, Murray CP, Stick SM. 2013. Risk factors for bronchiectasis in children with cystic fibrosis. N Engl J Med 368:1963–1970. https://doi.org/10.1056/ NEJMoa1301725.
  19. Gangell C, Gard S, Douglas T, Park J, De Klerk N, Keil T, Brennan S, Ranganathan S, Robins-Browne R, Sly PD, AREST CF. 2011. Inflammatory responses to individual microorganisms in the lungs of children with cystic fibrosis. Clin Infect Dis 53:425– 432. https://doi.org/10.1093/cid/ cir399.
  20. Ramsey KA, Ranganathan S, Park J, Skoric B, Adams AM, Simpson SJ, Robins-Browne RM, Franklin PJ, De Klerk NH, Sly PD, Stick SM, Hall GL. 2014. Early respiratory infection is associated with reduced spirometry in children with cystic fibrosis. Am J Respir Crit Care Med 190:1111–1116. https://doi.org/1164/rccm.201407-1277OC.
Ahead of Print Subscription Review Article
Volume
Received 28/09/2024
Accepted 05/10/2024
Published 08/10/2024
Views: 18

Check Our other Platform for Workshops in the field of AI, Biotechnology & Nanotechnology.
Learn more
Check Out Platform for Webinars in the field of AI, Biotech. & Nanotech.
Learn more